Kansai Medical University Hospital Administers First Dose of DS1025 in Global Phase 1 Trial Sponsored by Daiichi Sankyo
On August 18, 2026, Kansai Medical University Hospital administered the first dose of investigational drug DS1025 to a patient as part of a global Phase 1 clinical trial sponsored by Daiichi Sankyo. The trial is evaluating DS1025, an antibody-drug conjugate (ADC) targeting CD25-expressing Treg cells in patients with advanced solid tumors. DS1025 builds on Daiichi Sankyo's DXd ADC technology and aims to deplete immunosuppressive T-cells within the tumor microenvironment. The open-label, dose-escalation trial will assess safety, tolerability, pharmacokinetics, and preliminary efficacy in up to 45 patients across Asia and Europe. This milestone highlights Kansai Medical University Hospital's growing role in early-stage international cancer drug development, particularly in a region where access to first-in-human trials has been limited. The hospital is collaborating with Daiichi Sankyo and other partners to advance new approaches to cancer treatment.
Topics: antibody_drug_conjugate cancer_therapy immunotherapy pharmaceuticals